Abstract
Background Negative symptoms in schizophrenia are debilitating and lack effective treatments. Reward system dysfunction and cerebellum anomalies have been linked to negative symptoms. Evidence suggests the cerebellum modulates the reward system via the ventral tegmental area (VTA). The "cognitive dysmetria theory" posits that reduced cerebellar inhibition in schizophrenia may underlie striatal hyperdopaminergia. However, cerebellum-VTA connectivity and its impact on negative symptoms in schizophrenia remains unclear.
Method In a longitudinal study, we conducted interviews and acquired resting-state functional magnetic resonance imaging (rs-fMRI) in 146 individuals, including patients with schizophrenia (SZ) and healthy controls (HC). The Brief Negative Symptom Scale (BNSS) was used to quantify negative symptoms. After quality check, the final sample included 105 individuals (58 SZ) at baseline (T1), 41 individuals (22 SZ) at 3-month follow-up (T2), and 21 patients at 9-month follow-up (T3; interviews only). We analyzed the dynamic functional connectivity of cerebellum and VTA activity using Co-Activation Patterns (CAPs) analysis.
Results We identified a longitudinally stable anti-coactivation cerebellum-VTA pattern across baseline and T2 (rho = 0.98) encompassing bilateral paravermal regions of Crus I and II. Across all timepoints, the anti-coactivation spatial pattern’s persistence quantified by its duration, was significantly reduced in schizophrenia, indicating an enduring deficiency in cerebellar inhibition of the VTA. Lower emergence of this pattern at T1 and lower persistence at T2 were associated with more severe apathy but not diminished expression. Further, lower persistence at T2 predicted more severe apathy but not diminished expression 6 months later.
Conclusion These results provide stable longitudinal evidence on the cerebellum’s "dysmetric" regulatory effect on reward circuitry in schizophrenia and open the perspective for targeted cerebellar non-invasive brain stimulation to alleviate negative symptoms.
Competing Interest Statement
SK has received advisory board honoraria from Boehringer Ingelheim and Exeltis. The other authors report no conflicts of interests.
Funding Statement
Leenaards Foundation grant awarded to IB. Swiss National Science Foundation Grant No 169783 to SK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Geneva Ethics Committee in Switzerland gave approval for this work (CCER. BASEC ID: 2017-01765 and 2020-02169).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Shared authorship
Data Availability
Data will be available upon reasonable request to the authors.
